Free Trial
NASDAQ:HALO

Halozyme Therapeutics (HALO) Stock Price, News & Analysis

Halozyme Therapeutics logo
$57.15 -0.48 (-0.83%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$57.16 +0.01 (+0.02%)
As of 07/11/2025 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Halozyme Therapeutics Stock (NASDAQ:HALO)

Key Stats

Today's Range
$56.79
$57.86
50-Day Range
$47.91
$70.05
52-Week Range
$42.01
$70.51
Volume
1.24 million shs
Average Volume
1.76 million shs
Market Capitalization
$7.04 billion
P/E Ratio
15.20
Dividend Yield
N/A
Price Target
$62.50
Consensus Rating
Hold

Company Overview

Halozyme Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

HALO MarketRank™: 

Halozyme Therapeutics scored higher than 96% of companies evaluated by MarketBeat, and ranked 36th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Halozyme Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 4 buy ratings, 6 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Halozyme Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Halozyme Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Halozyme Therapeutics are expected to grow by 31.50% in the coming year, from $4.73 to $6.22 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Halozyme Therapeutics is 15.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.85.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Halozyme Therapeutics is 15.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.21.

  • Price to Earnings Growth Ratio

    Halozyme Therapeutics has a PEG Ratio of 0.38. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Halozyme Therapeutics has a P/B Ratio of 19.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Halozyme Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.35% of the float of Halozyme Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Halozyme Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Halozyme Therapeutics has recently decreased by 8.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Halozyme Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Halozyme Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.35% of the float of Halozyme Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Halozyme Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Halozyme Therapeutics has recently decreased by 8.04%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Halozyme Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Halozyme Therapeutics this week, compared to 12 articles on an average week.
  • Search Interest

    Only 1 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -96% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -69% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,533,884.00 in company stock.

  • Percentage Held by Insiders

    Only 2.40% of the stock of Halozyme Therapeutics is held by insiders.

  • Percentage Held by Institutions

    97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Halozyme Therapeutics' insider trading history.
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Stock News Headlines

This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
See More Headlines

HALO Stock Analysis - Frequently Asked Questions

Halozyme Therapeutics' stock was trading at $47.81 at the start of the year. Since then, HALO stock has increased by 19.5% and is now trading at $57.15.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its quarterly earnings results on Tuesday, May, 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics's quarterly revenue was up 35.2% compared to the same quarter last year.
Read the conference call transcript
.

Halozyme Therapeutics subsidiaries include Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.

Top institutional investors of Halozyme Therapeutics include Swedbank AB (0.13%), Livforsakringsbolaget Skandia Omsesidigt (0.08%), Redhawk Wealth Advisors Inc. (0.03%) and NorthCrest Asset Manangement LLC (0.02%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Jeffrey William Henderson, James M Daly and Nicole Labrosse.
View institutional ownership trends
.

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/06/2025
Today
7/12/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:HALO
CIK
1159036
Employees
390
Year Founded
1998

Price Target and Rating

High Price Target
$75.00
Low Price Target
$47.00
Potential Upside/Downside
+9.4%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.76
Trailing P/E Ratio
15.20
Forward P/E Ratio
12.08
P/E Growth
0.38
Net Income
$444.09 million
Net Margins
44.76%
Pretax Margin
55.79%
Return on Equity
136.91%
Return on Assets
26.05%

Debt

Debt-to-Equity Ratio
3.13
Current Ratio
8.39
Quick Ratio
7.30

Sales & Book Value

Annual Sales
$1.02 billion
Price / Sales
6.94
Cash Flow
$4.65 per share
Price / Cash Flow
12.28
Book Value
$2.86 per share
Price / Book
19.98

Miscellaneous

Outstanding Shares
123,220,000
Free Float
120,264,000
Market Cap
$7.04 billion
Optionable
Optionable
Beta
1.15

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:HALO) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners